tiprankstipranks
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market
ALNY
Alnylam Pharma
RESEARCH TOOLSreports
Want to see ALNY full AI Analyst Report?

Alnylam Pharma (ALNY) Income Statement

1,437 Followers

Alnylam Pharma Income Statement

Last quarter (Q1 2026), Alnylam Pharma's total revenue was $1.17B, an increase of 96.43% from the same quarter last year. In Q1, Alnylam Pharma's net income was $205.99M. See Alnylam Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 3.71B$ 2.25B$ 1.83B$ 1.04B$ 844.29M
Gross Profit
$ 3.04B$ 1.92B$ 1.52B$ 868.60M$ 704.14M
Operating Expenses
$ 2.54B$ 2.10B$ 1.80B$ 1.65B$ 1.41B
Depreciation and Amortization
$ 55.66M$ 56.67M$ 54.05M$ 44.47M$ 47.57M
EBITDA
$ 557.24M$ -178.85M$ -258.24M$ -926.56M$ -661.56M
Operating Income
$ 501.58M$ -176.88M$ -282.18M$ -785.07M$ -708.65M
Other Income/Expenses
$ -178.43M$ -200.49M$ -151.34M$ -341.92M$ -143.49M
Pretax Income
$ 323.15M$ -377.38M$ -433.52M$ -1.13B$ -852.14M
Net Income
$ 313.75M$ -278.16M$ -440.24M$ -1.13B$ -852.82M
Per Share Metrics
Basic EPS
$ 2.39$ -2.18$ -3.52$ -9.30$ -7.20
Diluted EPS
$ 2.33$ -2.18$ -3.52$ -9.30$ -7.20
Weighted Average Shares Outstanding
 131.00M 127.65M 124.91M 121.69M 118.45M
Weighted Average Shares Outstanding (Diluted)
 134.68M 127.65M 124.91M 121.69M 118.45M
Currency in USD

Alnylam Pharma Earnings and Revenue History